Autopsy report · NCT06523725

Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy

“Company decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Dr. Paul Lyons

Sponsor type

University, hospital or other

Conditions

Post-traumatic Epilepsy

Interventions

PO BRC-003 (High Cannabidiol Cannabis Extract); Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (92% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (90% match in meaning)
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.